Multimodality Treatments in Metastatic Gastric Cancer
Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of spec...
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Assuntos: | |
| Acesso em linha: | ONIX_20220111_9783036525921_909 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869521873608376320 |
|---|---|
| collection | Directory of Open Access Books |
| description | Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics. |
| format | Online |
| id | doab-20.500.12854ir-77077 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-770772024-03-30T23:22:56Z Multimodality Treatments in Metastatic Gastric Cancer Petrillo, Angelica advanced gastric cancer precision medicine new drug development gastro-oesophageal cancer mutational concordance exome sequencing formalin fixed paraffin embedded biomarkers gastric cancer metastatic body composition sarcopenia visceral fat area subcutaneous fat area outcome toxicity liver metastasis conversion surgery hepatectomy stage iv gastric cancer immune checkpoint inhibitors Epstein Barr Virus tumor mutational burden microsatellite instability predictive biomarkers CAR T cell therapy vaccines nutritional status metastatic gastric cancer target therapy bone flare stage IV treatment RANK-L liquid biopsy circulating tumor cell cfDNA ctDNA epithelial–mesenchymal transition resistance to treatment HER2-inhibition VEGFR-inhibition immunotherapy response monitoring n/a thema EDItEUR::M Medicine and Nursing Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics. 2022-01-11T13:51:28Z 2022-01-11T13:51:28Z 2021 book ONIX_20220111_9783036525921_909 9783036525921 9783036525938 https://directory.doabooks.org/handle/20.500.12854/77077 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4696 https://mdpi.com/books/pdfview/book/4696 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2593-8 10.3390/books978-3-0365-2593-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036525921 9783036525938 162 Basel, Switzerland open access |
| spellingShingle | advanced gastric cancer precision medicine new drug development gastro-oesophageal cancer mutational concordance exome sequencing formalin fixed paraffin embedded biomarkers gastric cancer metastatic body composition sarcopenia visceral fat area subcutaneous fat area outcome toxicity liver metastasis conversion surgery hepatectomy stage iv gastric cancer immune checkpoint inhibitors Epstein Barr Virus tumor mutational burden microsatellite instability predictive biomarkers CAR T cell therapy vaccines nutritional status metastatic gastric cancer target therapy bone flare stage IV treatment RANK-L liquid biopsy circulating tumor cell cfDNA ctDNA epithelial–mesenchymal transition resistance to treatment HER2-inhibition VEGFR-inhibition immunotherapy response monitoring n/a thema EDItEUR::M Medicine and Nursing Multimodality Treatments in Metastatic Gastric Cancer |
| title | Multimodality Treatments in Metastatic Gastric Cancer |
| title_full | Multimodality Treatments in Metastatic Gastric Cancer |
| title_fullStr | Multimodality Treatments in Metastatic Gastric Cancer |
| title_full_unstemmed | Multimodality Treatments in Metastatic Gastric Cancer |
| title_short | Multimodality Treatments in Metastatic Gastric Cancer |
| title_sort | multimodality treatments in metastatic gastric cancer |
| topic | advanced gastric cancer precision medicine new drug development gastro-oesophageal cancer mutational concordance exome sequencing formalin fixed paraffin embedded biomarkers gastric cancer metastatic body composition sarcopenia visceral fat area subcutaneous fat area outcome toxicity liver metastasis conversion surgery hepatectomy stage iv gastric cancer immune checkpoint inhibitors Epstein Barr Virus tumor mutational burden microsatellite instability predictive biomarkers CAR T cell therapy vaccines nutritional status metastatic gastric cancer target therapy bone flare stage IV treatment RANK-L liquid biopsy circulating tumor cell cfDNA ctDNA epithelial–mesenchymal transition resistance to treatment HER2-inhibition VEGFR-inhibition immunotherapy response monitoring n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | advanced gastric cancer precision medicine new drug development gastro-oesophageal cancer mutational concordance exome sequencing formalin fixed paraffin embedded biomarkers gastric cancer metastatic body composition sarcopenia visceral fat area subcutaneous fat area outcome toxicity liver metastasis conversion surgery hepatectomy stage iv gastric cancer immune checkpoint inhibitors Epstein Barr Virus tumor mutational burden microsatellite instability predictive biomarkers CAR T cell therapy vaccines nutritional status metastatic gastric cancer target therapy bone flare stage IV treatment RANK-L liquid biopsy circulating tumor cell cfDNA ctDNA epithelial–mesenchymal transition resistance to treatment HER2-inhibition VEGFR-inhibition immunotherapy response monitoring n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220111_9783036525921_909 |